|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Pennsylvania Ave., NW |
Address2 | Suite 530 |
| City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103493-101
|
||||||||
|
6. House ID# 427640010
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kristi L. Remington |
Date | 1/21/2020 4:45:51 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics, including Affordable Insulin Approvals Now Act, S. 2103;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ashley |
Davis |
|
|
|
Malloy |
McDaniel |
|
|
|
Kristi |
Remington |
|
|
|
Shimon |
Stein |
|
|
|
Craig |
Kalkut |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan N.V. and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ashley |
Davis |
|
|
|
Malloy |
McDaniel |
|
|
|
Kristi |
Remington |
|
|
|
Shimon |
Stein |
|
|
|
Craig |
Kalkut |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan N.V. and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ashley |
Davis |
|
|
|
Malloy |
McDaniel |
|
|
|
Kristi |
Remington |
|
|
|
Shimon |
Stein |
|
|
|
Craig |
Kalkut |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan N.V. and Mylan Holdings Limited have a general interest in the issues above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ashley |
Davis |
|
|
|
Craig |
Kalkut |
|
|
|
Malloy |
McDaniel |
|
|
|
Kristi |
Remington |
|
|
|
Shimon |
Stein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent entities of Mylan Inc., Mylan N.V. and Mylan Holdings Limited have a general interest in the issues above.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |